We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Autosomal Dominant Disorder Confirmed by Biomarker Assay

By LabMedica International staff writers
Posted on 06 Feb 2012
Print article
The erythrocyte glucose-uptake assay has been used to confirm the diagnosis of glucose transporter type 1 deficiency syndrome (Glut1-DS).

The disease is diagnosed with cerebrospinal fluid (CSF) glucose values of less than 2.2 mmol/L, or lowered CSF/plasma glucose ratio of less than 0.4, and the erythrocyte 3-O-methyl-d-glucose uptake assay (3-OMG).

Scientists at Columbia University (New York, NY, USA) studied 109 suspected cases of Glut-1 DS, all who had a consistent clinical picture and a low CSF glucose concentration (hypoglycorrhachia). To confirm the diagnosis of Glut1 DS, blood samples from both patients and parents were analyzed using the erythrocyte 3-OMG uptake assay. The erythrocytes are radioactively labeled and measured on a scintillation counter.

Copy number analysis was performed via single nucleotide polymorphism (SNP) oligonucleotide microarray analysis (SOMA) using the Affymetrix Genome Wide Human SNP Array 6.0 (Santa Clara, CA, USA), which includes over 906,600 SNPs and more than 946,000 probes for the detection of copy number variation. A multiplex ligation-dependent probe amplification (MLPA) kit (MRC-Holland; Amsterdam, Netherlands) was used to screen eight patients with decreased 3-OMG uptake without identified sequence based mutations or deletions using SOMA. .

The uptake assay was decreased in 74 cases (group 1) and normal in 35 cases (group 2). The disease-causing mutations were identified in 70 group 1 patients (95%) and only one in group 2 patients (3%). The cut-off for an abnormally low uptake value was increased from 60% to 74% with a corresponding sensitivity of 99% and specificity of 100%. The correlation between the uptake values for the time-curve and the kinetic concentration curve were strongly positive. There was a significant correlation between the mean erythrocyte 3-OMG uptake and clinical severity.

The authors concluded that the erythrocyte glucose-uptake assay, when abnormal, essentially confirms the clinical suspicion of Glut1 DS. Furthermore, the degree of uptake abnormality correlates with glucose transport functional activity and has implications regarding clinical severity and prognosis. Glut1 deficiency syndrome is characterized classically by infantile onset seizures, delayed neurological development, disorders of movement, and acquired microcephaly. The study was published in December 2011, in the Annals of Neurology.

Related Links:

Columbia University
Affymetrix
MRC-Holland


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TETANUS Test
TETANUS VIRCLIA IgG MONOTEST
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.